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Abstract Purpose of this study was to assess the
additional value of ﬁrst pass myocardial perfusion
imaging during peak dose of dobutamine stress
Cardiac-MR (CMR). Dobutamine Stress CMR
was performed in 115 patients with an inconclu-
sive diagnosis of myocardial ischemia on a 1.5 T
system (Magnetom Avanto, Siemens Medical
Systems). Three short-axis cine and grid series
were acquired during rest and at increasing doses
of dobutamine (maximum 40 lg/kg/min). On
peak dose dobutamine followed immediately by
a ﬁrst pass myocardial perfusion imaging se-
quence. Images were graded according to the
sixteen-segment model, on a four point scale.
Ninety-seven patients showed no New (Induced)
Wall Motion Abnormalities (NWMA). Perfusion
imaging showed absence of perfusion deﬁcits in
67 of these patients (69%). Perfusion deﬁcits
attributable to known previous myocardial infarc-
tion were found in 30 patients (31%). Eighteen
patients had NWMA, indicative for myocardial
ischemia, of which 14 (78%) could be conﬁrmed
by a corresponding perfusion deﬁcit. Four pa-
tients (22%) with NWMA did not have perfusion
deﬁcits. In these four patients NWMA were
caused by a Left Bundle Branch Block (LBBB).
They were free from cardiac events during the
follow-up period (median 13.5 months; range
6–20). Addition of ﬁrst-pass myocardial perfusion
imaging during peak-dose dobutamine stress
CMR can help to decide whether a NWMA is
caused by myocardial ischemia or is due to an
(inducible) LBBB, hereby preventing a false
positive wall motion interpretation.
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Introduction
Dobutamine stress Cardiac MRI (CMR) is used
to detect myocardial ischemia of the left ventricle
by means of wall motion analysis during the
infusion of high-dose dobutamine [1–4]. Previous
studies have reported a broad range of sensitivity
(83–91%) and speciﬁcity (80–86%) of dobuta-
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ischemia [1–3, 5]. It has been proven to be more
accurate than dobutamine stress echocardiogra-
phy [2]. The addition of myocardial tagging even
further increased the sensitivity (96%) of dobu-
tamine stress CMR [4]. False positive dobutamine
stress CMR’s were described for left bundle
branch block (LBBB) or an incidental low inter-
pretability [4]. Means to overcome for these false-
positive dobutamine stress CMR’s could increase
speciﬁcity even further.
Assessment of myocardial perfusion is used to
provide information on the hemodynamic signif-
icance of a coronary artery stenosis. Segments
with New Wall Motion Abnormalities (NWMA)
detected with dobutamine stress CMR should
also show perfusion deﬁcits, since perfusion
abnormalities precede wall motion abnormalities
in the ischemic cascade [6].
Normal stress perfusion SPECT-results predict
a less than 1% annual risk of cardiac death or
myocardial infarction, thereby yielding a high
negative predictive value [7–10]. High negative
predictive values are also reported for MR
perfusion imaging combined with MRI cine-
angiography (100%) in a small study of 15
patients [11].
The addition of a perfusion sequence on peak-
dose dobutamine may further enhance the inter-
pretation of dobutamine stress CMR, by ruling
out false positive ﬁndings, through the combined
strength of both methods.
The purpose of this study is to assess whether
the addition of perfusion imaging to dobutamine
stress CMR at peak-dose dobutamine reduces the
number of false-positive dobutamine stress CMR
examinations.
Materials and methods
Patient population
Between September 2004 and April 2006, 124
consecutive patients were referred from the
department of Cardiology for a dobutamine stress
CMR. The study was approved by the local
ethical committee. Informed consent was
obtained prior to the study, after the nature of
the procedure had been explained. All patients
had chest pain and an inconclusive diagnosis of
coronary artery disease by means of history, ECG
recordings at rest and, if performed, during a
bicycle exercise test. Patients with an acute
coronary syndrome, atrial ﬁbrillation, severe
arterial hypertension (>220/120), CMR-incom-
patible metallic implants or known claustropho-
bia were not eligible.
Protocol for dobutamine stress CMR
with myocardial perfusion on peak-dose
dobutamine
To ensure cardiac response to dobutamine, all
anti-anginal medication was stopped 4 days be-
fore the dobutamine stress CMR examination.
After the patient was positioned on the scanning
table, intravenous access was established via an
anticubital vein. ECG monitoring leads, a phased-
array surface coil covering the heart, and a
brachial blood pressure cuff were applied. A
single lead ECG was continuously monitored on
the MRI-console. Systolic and diastolic blood
pressures were recorded using an automatic
device (Welch-Allyn, Emro-medical) at baseline
and every 3 min throughout the procedure. Blood
pressure and heart rate were recorded. The
imaging methodology of dobutamine stress
CMR has been described in detail previously
[4]. Dobutamine stress CMR was performed on a
1.5 T system (Magnetom Avanto, Siemens
Medical Systems, Erlangen, Germany). Three
short-axis cine breath-hold CMR images of the
left ventricle, with and without myocardial tag-
ging, were acquired at rest and during incremen-
tal dosage of dobutamine up to 40 lg/kg/min. An
ECG-triggered segmental gradient-echo pulse
sequence was used: TrueFisp: TR 57.64, ms; TE,
1.1 ms; a,5 9  ; FOV, 284 · 350 mm; slice-thick-
ness 6 mm; and matrix 125 · 192; iPAT 2.
Tagging was performed with a standard FLASH
grid-sequence: TR, 46 ms; TE, 3.8 ms; a,1 4  ;
FOV, 284 · 350 mm; slice-thickness 6 mm and
matrix 141 · 256. The basal plane was taken
1.5 cm below the mitral valves. The midventric-
ular and apical short-axis views were divided
equally over the remaining part of the left
ventricle. When a wall motion abnormality
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123(WMA) was detected at baseline, infusion was
started at 5 lg/kg/min, after which the dose
of dobutamine was increased to 10, 20, 30 and
40 lg/kg/min. Starting dose of dobutamine was
10 lg/kg/min when no WMA was detected at
baseline. Imaging started 6 min after each dose
increase and required 3 min per dose increase.
Termination criteria for dobutamine stress
CMR were the development of new wall motion
abnormalities (NWMA) or worsening WMA, a
fall of systolic blood pressure of more than
40 mmHg, marked hypertension above 240/
120 mmHg, severe chest pain, ventricular
arrhythmias and intolerable side effects. NWMA
are indicative of myocardial ischemia.
On peak-dose dobutamine a bolus injection of
0.1 mmol/kg gadolinium-DTPA (Omniscan
 )
was given and a perfusion sequence was started:
TrueFisp: TR, 150.5 or 163.1 ms; TE 1.03 ms; TI
100/103 ms; a 45/50 ; FOV 300 · 300; slice-thick-
ness 6 mm; matrix 76 · 128; iPAT 2. The same
three slices as the cine and tagging series were
acquired.
During the examination a radiologist present in
the MR suite to monitor the condition of the
patient and to visually evaluate the images. When
NWMA’s with a corresponding perfusion deﬁcit
were seen, a coronary angiography (CAG) was
performed within 3 weeks. Patients with
NWMA’s and a normal ﬁrst pass perfusion on
peak stress entered follow-up.
Image analysis
Wall motion was scored on six segments of
the basal plane, six on the midventricular plane
and four on the apical plane. Segmental wall
motion was qualitatively graded as 1 = normal
or hyperkinesis; 2 = hypokinesis; 3 = akinesis;
and, 4 = dyskinesis. Myocardial ischemia was
deﬁned as a new (induced) or worsening WMA
in at least two segments at consecutive planes
of the left ventricle during infusion of dobuta-
mine. Analysis was performed using both cine
and tagging images as described in detail previ-
ously [4].
Wall Motion Score Index (WMSI) was derived
as the mean score of all segments of all short-axis
images. WMSI data from the combined analysis
of the cine and tagging images were determined
from baseline and peak stress images.
The ﬁrst pass perfusion images on peak-dose
dobutamine were visually analyzed by an expe-
rienced radiologist and cardiologist in a consen-
sus reading after the wall motion analysis by the
same physicians. A perfusion abnormality, cor-
responding to the coronary artery distribution
areas, in at least two segments at consecutive
short-axis slices or one segment of the most
apical slice of the left ventricle was deﬁned as
myocardial ischemia.
Follow-up
Follow-up data were obtained in September
2006. The present status of the patient was
determined by review of the hospital records or
contacting the patient’s general physician. The
date of the last review was used to calculate
follow-up time.
Evaluated end points were non-fatal myocar-
dial infarction (angina of >30 min duration and
either 2 mm ST segment elevation in two consec-
utive ECG leads or a rise in creatine kinase level
and its myoglobine fraction two times the upper
limit of normal), cardiac death (death in the
presence of acute myocardial infarction, signiﬁ-
cant cardiac arrhythmias or refractory congestive
heart failure) and coronary revascularization.
Results
Patient population
From the 124 consecutively included patients, in
nine patients the examination could not be
completed due to: intolerable side effects
(nausea, vomiting) in four patients, claustropho-
bia in three patients. Two patients were excluded
due to insufﬁcient image quality, one of whom
had an irregular rhythm with triggering difﬁcul-
ties, and the other patient was unable to sustain
breath holds.
Therefore, 115 patients all with good image
quality were analysed (93%) with a mean age
61 ± 11 years, 20 women (30%). Demographic
and hemodynamic data are listed in Table 1.
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perfusion on peak-dose dobutamine
Eighteen of the 115 patients (16%) had
NWMA of whom 14 (78%) showed perfusion
deﬁcits on peak-dose dobutamine in the
corresponding segments. Four patients (22%)
with NWMA did not have a perfusion deﬁcit.
In these four patients, NWMA were attribut-
able to a LBBB as could be conﬁrmed with an
independent (stress) ECG. Two of these were
inducible LBBB, not known prior to the
examination. CAG was positive for the corre-
sponding segments in the 14 patients (100%)
with NWMA and a corresponding perfusion
deﬁcit.
Ninety-seven patients (84%) had no NWMA.
The perfusion images on peak-dose dobutamine
showed absence of perfusion deﬁcits in 67 of these
97 patients (69%) and perfusion deﬁcts in 30
(31%). Of these patients 29 (97%) were attribut-
able to a known previous myocardial infarction in
the patients history combined with the presence of
RWMA. One patient (3%) had a small perfusion
deﬁcit inferior which could not be assigned to a
known previous event in the patients history.
Figure 1 illustrates the course and outcome of the
study. In Fig. 2 the additional value of cine or grid
tagging images combined with stress ﬁrst-pass
perfusion images is illustrated.
Follow-up results (median 13.5 months, range
6–20 months) were obtained from all patients
with NWMA’s and a normal ﬁrst-pass perfusion.
None of these patients had cardiac events or
revascularizations at follow-up.
Table 1 Demographic and hemodynamic data
Variable Mean or %
Age, years 61 ± 11
Female, % 29.6
Previous myocardial infarction, % 38.0
Revascularization, % 31.0
Rest wall motion abnormalities
(RWMA), %
40.9
Body weight, kg 78 ± 12
Resting diastolic blood pressure, mmHg 87 ± 11
Peak diastolic blood pressure, mmHg 78 ± 12
Resting systolic blood pressure, mmHg 152 ± 26
Peak systolic blood pressure, mmHg 151 ± 31
Resting heart rate, bpm 79 ± 15
Peak heart rate, bpm 119 ± 21
Rate-pressure product
a at rest 12,030 ± 3,545
Rate-pressure product at peak stress 17,935 ± 4,807
Wall Motion Score Index (WMSI) at
baseline
1.18 ± 0,32
Wall Motion Score Index (WMSI) at peak
dose
1.21 ± 0.34
Values are expressed as mean ± SD or percentage
aRate-pressure product = (heart rate) · (systolic blood
pressure)
RWMA = Rest Wall Motion Abnormality; WMSI = Wall
Motion Score Index
Fig. 1 Flow chart
illustrating course of the
study and outcome
NWMA = New Wall
Motion Abnormality;
LBBB = Left Bundle
Branch Block;
CAG = Coronary
Angiogram
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This study demonstrates that adding ﬁrst-pass
myocardial perfusion imaging during peak-dose
dobutamine has direct clinical relevance for the
interpretation of dobutamine stress CMR exam-
inations, by increasing the interpretation of pos-
sible wall motion abnormalities (NWMA) of the
left ventricle. The addition of ﬁrst pass perfusion
relies on the conceptual use of the ischemic
cascade. Ischemic wall motion abnormalities are
preceded by perfusion abnormalities, therefore
visualized NWMA due to myocardial ischemia
should also show perfusion abnormalities. A
normal perfusion study is used to identify wall
motion abnormalities not due to myocardial
ischemia, and an abnormal corresponding perfu-
sion deﬁcit is used to conﬁrm NWMA, indicative
for myocardial ischemia.
This is the ﬁrst study to assess the additional
value of a ﬁrst pass myocardial perfusion imaging
sequence on peak-dose dobutamine during a
dobutamine stress CMR. Previous studies have
reported a broad range of sensitivity and speci-
ﬁcity for dobutamine stress CMR in the detection
of myocardial ischemia [4]. In this protocol we
have chosen for a prolonged infusion time of
dobutamine from 3 to 6 min without atropine and
the use of the target heart rate rule, as described
before [4, 12–17].
The use of the target heart rate rule from a
physical exercise based concept can not be
generalized to a pharmacological stress setting
and has been questioned in several reports
[12–14, 18]. It has also been shown that the target
heart rate rule can not be extrapolated to a
pharmacological stress examination [19]. In a
recent overview of published dobutamine stress
CMR examinations by Strach et al. [20], the
approach we used [4] showed to provide the
highest diagnostic accuracy for signiﬁcant coro-
nary artery disease deﬁned by a >50% luminal
stenosis on a coronary angiogram. Speciﬁcity,
although already high, was lowered, according to
Fig. 2 Short axis views at
peak-dose dobutamine.
Cine image illustrating a
NWMA inferior. (A)
Perfusion abnormality in
the corresponding
segment. (B) Dyskinetic
septal wall in another
patient. (C) No perfusion
abnormalities in the
corresponding segment.
(D) Dyskinetic septal wall
in C was due to a LBBB,
this differentiation could
be made by a perfusion
sequence on peak-dose
dobutamine. Arrows
indicate the wall motion
abnormality or perfusion
abnormality
NWMA = New Wall
Motion Abnormality;
LBBB = Left Bundle
Branch Block
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overcome with a perfusion sequence, taking into
account the high negative predictive value of
normal myocardial perfusion imaging. The addi-
tional value of myocardial perfusion MRI could
be used for this purpose and may add signiﬁcant
diagnostic information.
In this study we added a perfusion sequence on
peak-dose dobutamine in all patients. The results
show a good agreement between the absence of
NWMA and myocardial perfusion. The main
purpose of this study was to assess the additional
value of ﬁrst-pass perfusion imaging in the pres-
ence of NWMA. Our recommendation for future
clinical use is to add a ﬁrst pass perfusion
sequence on indication, namely if there is doubt
on whether a NWMA is due to myocardial
ischemia. In this way, the speciﬁcity of dobuta-
mine stress CMR can be even further increased.
By combining dobutamine stress CMR with
myocardial perfusion, one still has the opportu-
nity to examine for viability, which seems even
superior to scar quantiﬁcation [21].
Absolute speciﬁcity values cannot be given
with this study, because a CAG was not per-
formed in case of a negative dobutamine stress
examination. The outcome of the dobutamine
stress CMR and myocardial perfusion on peak-
dose dobutamine was used as a direct arbiter for
subsequent clinical follow-up. In this respect
follow-up was considered the reference standard.
None of the patients with NWMA’s and a normal
myocardial perfusion had an adverse outcome at
follow-up. Therefore, it is reasonable to state that
adding ﬁrst pass myocardial perfusion imaging on
peak-dose dobutamine increases the speciﬁcity of
dobutamine stress CMR in this patient group.
Our data could have been inﬂuenced by a
referral bias, but in light of previous results, we
found it not justiﬁable to perform a CAG in case
of a negative examination [12]. Furthermore, the
high negative predictive value of dobutamine
stress CMR examination without perfusion imag-
ing has been proven before [12, 22]. Mahrholdt
et al. [23]. examined 139 patients with a LBBB.
All 139 patients had ﬁxed perfusion defects with
SPECT, 19 could not be conﬁrmed with CAG.
Rest wall motion analysis and myocardial perfu-
sion (between 5 and 30 min after contrast admin-
istration) was performed on these 19 patients
using MRI. All 19 patients showed septal wall
motion abnormalities, but none showed subendo-
cardial or transmural contrast enhancement. This
also indicates that contrast enhanced imaging can
help differentiate between WMA on the basis of
coronary artery disease or a LBBB.
Long term follow-up will provide information
about the case in which a small perfusion abnor-
mality was seen inferior without NWMA.
Whether this abnormality is a ‘‘true’’ abnormality
or an artefact is unclear. This patient did not have
any adverse cardiac event at 14 months follow-up.
Another limitation of our study is the fact that
images were analysed semi-quantitatively. Quan-
titative wall motion analysis could possibly pro-
vide additional information, but due to the time-
consuming nature this is not yet feasible in clinical
practice. Furthermore, no decisions can be made
during the examination, which we believe is
crucial, since overstressing may lead to serious
complications [13].
Visual analysis of wall motion and perfusion
images was performed in a consensus reading by
an experienced radiologist and cardiologist. This
can be regarded as a limitation since the observ-
ers are not blinded for the previous wall motion
images. However, this does represent routine
clinical practice and is fundamental to the under-
lying concept of using ﬁrst-pass perfusion imaging
in the presence of NWMA. In recent studies the
inter-observer agreement of dobutamine stress
CMR was investigated and good agreement was
found [24, 25].
In a clinical post-infarct setting, delayed con-
trast enhancement imaging may provide valuable
diagnostic information. To our opinion, this
would in our study not have provided additional
information regarding the fact whether a NWMA
was caused by myocardial ischemia or a non-
ischemic cause, and guide the necessity for an
invasive coronary angiogram. Cine and grid
tagging images were acquired at rest to look for
rest wall motion abnormalities. New wall motion
abnormalities in this setting would represent
myocardial ischemia (whether or not in the
presence of a previous myocardial infarction).
Delayed contrast enhancement imaging was
therefore not performed in this protocol.
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pass perfusion images. Perfusion imaging at rest
may be very useful in stress-rest perfusion imag-
ing studies, but the main focus in this protocol is
on a normal perfusion in case of NWMA. A rest
perfusion exam would in this context not provide
additional information (the rest perfusion exam
will also be normal). In this way the protocol is
not unnecessarily prolonged and a second bolus
injection of gadolinium-DTPA can be omitted.
Conclusion
Good agreement exists between the absence of
NWMA and a normal myocardial perfusion.
Furthermore, a perfusion sequence on peak-dose
dobutamine can help decide whether a NWMA is
caused by ischemia or is due to a LBBB. First
pass myocardial perfusion during peak-dose
dobutamine can be used as an additional tool to
reduce the number of false-positive NWMA’s, to
improve the detection of myocardial ischemia.
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